Most dual target drugs are dual receptor agonists
1,2 It has revolutionized diabetes management, but its ocular effects require careful consideration especially for patients with diabetic retinopathy or those planning on elective surgery requiring sedation, such as cataract surgery
The suit tests whether inducement (271(b)) can reach a platform that coordinates API suppliers, compounding pharmacies, and prescribers without making the drug, alongside direct-infringement claims under 271(a)
[1] [4] It represents a novel therapeutic class as the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
Lipid Profiles: Retatrutide has shown a consistent ability to lower LDL (bad) cholesterol and triglycerides while maintaining or slightly increasing HDL (good) cholesterol
Provides gastroprotective effects against damage from NSAIDs and other medications that commonly irritate the digestive tract, supporting safe long-term pharmaceutical use when medically necessary